Marco Boorsma PhD
General Partner
Purespring is leading a revolution in the treatment of kidney diseases. More than 8 million people in the UK and 840 million people globally suffer from chronic kidney disease.
Purespring Therapeutics is a pioneering gene therapy company focused on transforming the treatment of kidney diseases.
Purespring is the first company to successfully treat kidney disease models by directly targeting the podocyte, a specialised cell implicated in approximately 60% of renal diseases, through its proprietary adeno-associated viral (AAV) gene therapy platform. The Company currently has a pipeline of programmes in development. This includes its lead programme PS-002, in development for IgA Nephropathy (IgAN), and other complement mediated kidney diseases, a programme targeting nephrotic syndrome, and an undisclosed glomerular kidney disease programme.
Purespring’s platform technology allows working copies of genes to be delivered with high efficiency and specificity to podocytes, opening up a new and highly differentiated modality for disease modifying treatments of a broad range of kidney diseases.
Industry
Biotech
Status
Current
Location
UK
Purespring has made remarkable strides in its approach to revolutionise the treatment of kidney disease, and we are solidifying our position as leaders in precision nephrology. We are set to enter the clinic later this year following regulatory approvals in the US, Europe and the UK for our Phase I/II trial in IgA nephropathy (IgAN). With Forbion as a key partner, we benefit from unwavering support from a team that embraces opportunity and innovation. They have provided us with the right balance of productive challenge and insightful guidance, while at the same time empowering us to drive strategy and execution as we transition to becoming a clinical-stage companyHaseeb Ahmad
CEO
